Abstract
A novel therapeutic strategy to prevent or reverse ventricular remodeling, the substrate for heart failure and arrhythmias following a myocardial infarction, is the use of cell-based therapy. Successful cell-based tissue regeneration involves a complex orchestration of cellular and molecular events that include stem cell engraftment and differentiation, secretion of anti-inflammatory and angiogenic mediators, and proliferation of endogenous cardiac stem cells. Recent therapeutic approaches involve bone marrow-derived mononuclear cells and mesenchymal stem cells, adipose tissue-derived stem cells, cardiac-derived stem cells and cell combinations. Clinical trials employing mesenchymal stem cells and cardiac-derived stem cells have demonstrated efficacy in infarct size reduction and regional wall contractility improvement. Regarding delivery methods, the safety of catheter-based, transendocardial stem cell injection has been established. These proof-of-concept studies have paved the way for ongoing pivotal trials. Future studies will focus on determining the most efficacious cell type(s) and/or cell combinations and the mechanisms underlying their therapeutic effects.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 17-24 |
| Number of pages | 8 |
| Journal | Regenerative Medicine |
| Volume | 7 |
| Issue number | 6 SUPPL. |
| DOIs | |
| State | Published - Nov 2012 |
Keywords
- Cardiac stem cell
- Cell transplantation
- Heart failure
- Ischemic heart disease
- Mesenchymal stem cell
- Myocardial infarction
ASJC Scopus subject areas
- Biomedical Engineering
- Embryology